Phase 4Recruiting
Dabrafenib and/or Trametinib Rollover Study
Open Label, Multi-center Roll-over Study to Assess Long Term Safety in Patients Who Have Completed a Global Novartis or GSK Sponsored Dabrafenib and/or Trametinib Study
- Sponsor
- Novartis Pharmaceuticals (Industry)
- Enrollment
- 100 planned
- Conditions
- Melanoma; Non Small Cell Lung Cancer; Solid Tumor; Rare Cancers; High Grade Glioma
- Interventions
- dabrafenib; trametinib
- Ages
- adults, older adults
- Registry
- NCT03340506, CTIS2023-509318-13-00
Full record on ClinicalTrials.gov
From the registry
This study is to provide access for patients who are receiving treatment with dabrafenib and/or trametinib in a Novartis-sponsored Oncology Global Development, Global Medical Affairs or a former GSK-sponsored study who have fulfilled the requirements for the primary objective, and who are judged by the investigator as benefiting from continued treatment in the parent study as judged by the Investigator at the completion of the parent study.
Primary outcomes
- Occurences of adverse events to evaluate long term safety and tolerability of dabrafenib, trametinib or combination
History
Primary completion expected
Last registry update
Started
Registered